U.S. Food and Drug Administration staff reviewers on Friday identified safety and efficacy concerns about Cytokinetics Inc.’s heart drug, according to briefing documents published on the agency’s website.
https://www.pharmalive.com/wp-content/uploads/2021/02/Becton-Dickinsons-combination-test-for-COVID-19-gets-FDA-authorization-Reuters-2-12-21.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-12-09 09:54:212022-12-09 12:35:11FDA staff reviewers flag safety concerns over Cytokinetics’ heart drug
